Akili Reports FDA Clearance Of EndeavorOTC (AKL-T01) As An Over-the-counter Treatment For Adults With Attention-deficit/Hyperactivity Disorder
Portfolio Pulse from Benzinga Newsdesk
Akili has received FDA clearance for EndeavorOTC (AKL-T01) as an over-the-counter treatment for adults with Attention-deficit/Hyperactivity Disorder (ADHD).
June 18, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akili has received FDA clearance for its product EndeavorOTC (AKL-T01) as an over-the-counter treatment for adults with ADHD. This regulatory approval could significantly boost the company's market presence and revenue.
The FDA clearance for EndeavorOTC (AKL-T01) as an over-the-counter treatment for ADHD is a significant milestone for Akili. This approval opens up a new market segment and could lead to increased sales and revenue, positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100